Cargando…
Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Patients commonly present with advanced/unresectable HCC where several treatment options are not effective. In this review, the authors discuss the indications and usage of lenvatinib, a multikinase inhibitor, as first-lin...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527338/ https://www.ncbi.nlm.nih.gov/pubmed/34712825 http://dx.doi.org/10.5114/ceh.2021.109312 |